IL176999A0 - Treatment of psychoses with quetiapine antipsychotic - Google Patents

Treatment of psychoses with quetiapine antipsychotic

Info

Publication number
IL176999A0
IL176999A0 IL176999A IL17699906A IL176999A0 IL 176999 A0 IL176999 A0 IL 176999A0 IL 176999 A IL176999 A IL 176999A IL 17699906 A IL17699906 A IL 17699906A IL 176999 A0 IL176999 A0 IL 176999A0
Authority
IL
Israel
Prior art keywords
psychoses
quetiapine
antipsychotic
treatment
quetiapine antipsychotic
Prior art date
Application number
IL176999A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Ault Brian
Block Gilbert
Brecher Martin
Macfadden Wayne
Mccoy Robin
Minkwitz Margaret
Mullen Jamie
Wilson Ellis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Ault Brian, Block Gilbert, Brecher Martin, Macfadden Wayne, Mccoy Robin, Minkwitz Margaret, Mullen Jamie, Wilson Ellis filed Critical Astrazeneca Ab
Publication of IL176999A0 publication Critical patent/IL176999A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
IL176999A 2004-01-30 2006-07-20 Treatment of psychoses with quetiapine antipsychotic IL176999A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54061804P 2004-01-30 2004-01-30
PCT/SE2005/000094 WO2005072742A1 (en) 2004-01-30 2005-01-27 Treatment of psychoses with quetiapine antipsychotic

Publications (1)

Publication Number Publication Date
IL176999A0 true IL176999A0 (en) 2006-12-10

Family

ID=34826230

Family Applications (1)

Application Number Title Priority Date Filing Date
IL176999A IL176999A0 (en) 2004-01-30 2006-07-20 Treatment of psychoses with quetiapine antipsychotic

Country Status (13)

Country Link
US (2) US20050171088A1 (https=)
EP (1) EP1713488A1 (https=)
JP (1) JP2007520488A (https=)
KR (1) KR20070011276A (https=)
CN (1) CN1913902A (https=)
AU (1) AU2005209142A1 (https=)
BR (1) BRPI0507086A (https=)
CA (1) CA2495361A1 (https=)
IL (1) IL176999A0 (https=)
NO (1) NO20063856L (https=)
RU (1) RU2006130687A (https=)
WO (1) WO2005072742A1 (https=)
ZA (1) ZA200606128B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
JP2008526839A (ja) * 2005-01-07 2008-07-24 アストラゼネカ・アクチエボラーグ １１−ピペラジン−１−イルジベンゾ［ｂ，ｆ］［１，４］チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用
US8389510B2 (en) 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions
WO2008079848A1 (en) * 2006-12-20 2008-07-03 Astrazeneca Ab (Se/Se) Compounds and uses thereof
US8017785B2 (en) 2006-05-09 2011-09-13 Astrazeneca Ab Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
US8682445B2 (en) * 2006-07-28 2014-03-25 Cyberonics, Inc. Patient management system for treating depression using an implantable medical device
US8715699B2 (en) 2009-12-31 2014-05-06 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
WO2011112657A1 (en) 2010-03-11 2011-09-15 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
CN103180277A (zh) 2010-05-20 2013-06-26 塔格塞普特股份有限公司 制备芳基取代的烯属胺的新方法
CN102631350B (zh) * 2012-03-29 2013-10-16 南京正科制药有限公司 一种富马酸喹硫平与鲁拉西酮的复方制剂
CN102716133A (zh) * 2012-04-06 2012-10-10 中国人民解放军第三军医大学 喹硫平在制备预防和治疗自身免疫性疾病的药物中的应用
CN109464451B (zh) * 2019-01-15 2021-07-13 范崇桂 一种治疗神经衰弱的药物及其制备方法
RU2717939C1 (ru) * 2019-10-29 2020-03-27 Государственное бюджетное учреждение Санкт-Петербургский научно-исследовательский институт скорой помощи им. И.И. Джанелидзе Способ лечения интоксикационных психозов при острых отравлениях психоактивными веществами

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
EP1073432B1 (en) * 1998-04-14 2007-08-15 The General Hospital Corporation Use of d-serine or d-alanine for treating schizophrenia
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US20030027817A1 (en) * 1998-05-29 2003-02-06 Tollefson Gary Dennis Combination therapy for treatment of bipolar disorders
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6194466B1 (en) * 1998-10-15 2001-02-27 Elizabeth Marie Cottingham Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
US20030096808A1 (en) * 1999-03-29 2003-05-22 Jon M. Miller Substance to prevent or reverse weight gain induced by psychoactive agents
US6489341B1 (en) * 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
US6350773B1 (en) * 1999-12-10 2002-02-26 American Home Products Corporation Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US20020061339A1 (en) * 2000-09-28 2002-05-23 Martin Stogniew Compositions and methods for use of extracts of rutaceae plants
US20050054942A1 (en) * 2002-01-22 2005-03-10 Melker Richard J. System and method for therapeutic drug monitoring
CA2431041A1 (en) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
US7053092B2 (en) * 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US7304047B2 (en) * 2001-02-06 2007-12-04 Astrazeneca Ab Method of treating substance abuse with quetiapine
US20020123490A1 (en) * 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
JP2004527553A (ja) * 2001-04-26 2004-09-09 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 抗痙攣性誘導体と非典型的抗精神病薬を用いた共治療を含んで成る精神病性障害治療
US6621096B2 (en) * 2001-05-21 2003-09-16 Hewlett-Packard Develpoment Company, L.P. Device isolation process flow for ARS system
JP2005503425A (ja) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
EP1397145B1 (en) * 2001-06-19 2006-09-06 Norbert Müller Use of cox-2 inhibitors for the treatment of schizophrenia, or tic disorders
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
AU2002319665B2 (en) * 2001-07-23 2006-09-21 Corcept Therapeutics, Inc. Methods for preventing antipsychotic-induced weight gain
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
GB0202900D0 (en) * 2002-02-07 2002-03-27 Laxdale Ltd Novel formulations of drugs
US6831077B2 (en) * 2002-07-25 2004-12-14 Comprehensive Neuroscience, Inc. Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation
US20040127489A1 (en) * 2002-07-29 2004-07-01 David Pickar Novel antipsychotic combination therapies and compositions useful therein
CA2529857A1 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
JP2006515628A (ja) * 2003-01-23 2006-06-01 アカディア ファーマシューティカルズ，インコーポレーテッド ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用
CA2525366A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
US20050171139A1 (en) * 2003-10-07 2005-08-04 Hammer Ronald P.Jr. Treating psychotic symptoms
JP2007509155A (ja) * 2003-10-21 2007-04-12 アルファーマ インコーポレイテッド クエチアピンを含有する薬剤
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
PT1696931E (pt) * 2003-12-22 2009-06-12 Acadia Pharm Inc Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas
WO2005063296A2 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
EP1715868A1 (en) * 2004-01-29 2006-11-02 Pfizer Products Incorporated Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
WO2005079807A1 (en) * 2004-02-13 2005-09-01 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
US20050181071A1 (en) * 2004-02-18 2005-08-18 Binder Michael R. Method for the treatment of clinical depression
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
MXPA06013163A (es) * 2004-05-11 2007-02-13 Pfizer Prod Inc Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US8285900B2 (en) * 2009-02-17 2012-10-09 The Board Of Regents Of The University Of Texas System Method and apparatus for congestion-aware routing in a computer interconnection network

Also Published As

Publication number Publication date
EP1713488A1 (en) 2006-10-25
NO20063856L (no) 2006-10-26
RU2006130687A (ru) 2008-03-10
CA2495361A1 (en) 2005-07-30
BRPI0507086A (pt) 2007-06-19
AU2005209142A1 (en) 2005-08-11
KR20070011276A (ko) 2007-01-24
JP2007520488A (ja) 2007-07-26
US20100311718A1 (en) 2010-12-09
ZA200606128B (en) 2007-11-28
WO2005072742A1 (en) 2005-08-11
US20050171088A1 (en) 2005-08-04
CN1913902A (zh) 2007-02-14

Similar Documents

Publication Publication Date Title
EP1667935A4 (en) TREATMENT OF ENVIRONMENTAL POLLUTANTS
ZA200606128B (en) Treatment of psychoses with quetiapine antipsychotic
IL178616A0 (en) Wastewater treatment
ZA200708033B (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
EP1960076A4 (en) TREATMENT OF HOSPITAL WASTE
ZA200706093B (en) Reducing by-catch of seabirds
EP1767565A4 (en) PROCESS FOR CLEANING OLIGOANILINES AND OLIGOANILINES
IL179779A0 (en) Sludge treatment process
GB0518508D0 (en) Treatment of waste
GB0424663D0 (en) Sludge treatment
GB2430002B (en) Well treatment
GB0426141D0 (en) Treatment
EP1793813A4 (en) TREATMENT OF HYPERACTIVITY DISORDER WITH DEFICIT ATTENTION (ADHD)
GB0426196D0 (en) Methods of treatment
GB0424085D0 (en) Well treatment
HK1096036A (en) Treatment of psychoses with quetiapine antipsychotic
GB0621587D0 (en) Sludge treatment
GB0423173D0 (en) Treatment of diabetes
GB2423766B (en) Treatment of waste materials
GB0414754D0 (en) Bath tap protector
GB0421176D0 (en) Treatment of atherosclerosis
HU0400952D0 (en) Treatment of anus-cancer
GB0408442D0 (en) Bath liner
AU2003272553A8 (en) Treatment of schizophrenia
GB0428337D0 (en) Waste treatment